All In Biotech

Drug Trial Radar · NCT07668388

A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

Efficacy and Safety of Once-weekly Subcutaneous UBT251 in Participants With Type 2 Diabetes - a Dose-finding Study

Last checked: Nov 19, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Jun 22, 2026

Primary completion

Oct 4, 2027

Study completion Nov 15, 2027

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Jun 25, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is testing UBT251 in participants with type 2 diabetes. The purpose of this clinical study is to find out if UBT251 is effective and safe for treating participants with type 2 diabetes. Participants will either get UBT251, UBT251 placebo, semaglutide, or semaglutide placebo. Which treatment participants get is decided by chance. UBT251 is the treatment being tested and is not yet available for doctors to prescribe, while semaglutide is a medicine used to treat type 2 diabetes that doctors can already prescribe.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • UBT251Drug

    UBT251 will be administered subcutaneously once-weekly.

  • UBT251 PlaceboDrug

    UBT251 placebo will be administered subcutaneously once-weekly.

  • SemaglutideDrug

    Semaglutide will be administered subcutaneously once-weekly.

  • Semaglutide PlaceboDrug

    Semaglutide placebo will be administered subcutaneously once-weekly.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. UBT251: Change in glycated haemoglobin (HbA1c)Time frame: From baseline (week 0) to 12 weeks on a given maintenance dose (week 16, 28 and 40)

Locations

70 sites in 9 countries. Site status is shown where the registry gives one.

  • Flourish Research

    Birmingham, Alabama · Recruiting

  • Ark Clinical Research

    Fountain Valley, California · Recruiting

  • Ark Clinical Research

    Long Beach, California · Recruiting

  • Los Angeles Institute for Metabolic Research

    Los Angeles, California · Recruiting

  • Catalina Research Institute, LLC

    Montclair, California · Recruiting

  • Encore Medical Research LLC

    Hollywood, Florida · Recruiting

  • South Broward Research LLC

    Miramar, Florida · Recruiting

  • Encore Medical Research of Weston

    Weston, Florida · Recruiting

  • Midwest Inst For Clin Res

    Indianapolis, Indiana · Not yet recruiting

  • Cotton O'Neil Diabetes & Endocrinology

    Topeka, Kansas · Recruiting

  • MD Medical Research

    Oxon Hill, Maryland · Recruiting

  • PharmQuest

    Greensboro, North Carolina · Not yet recruiting

  • KDCILM, LLC & Accellacare US, Inc.

    Wilmington, North Carolina · Recruiting

  • Plains Clinical Research Center, LLC_Fargo

    Fargo, North Dakota · Not yet recruiting

  • Preferred Primary Care Physicians, Inc.

    Uniontown, Pennsylvania · Recruiting

  • Monroe Biomedical Research, LLC

    North Charleston, South Carolina · Recruiting

  • LifeDoc Health

    Memphis, Tennessee · Recruiting

  • IMA Clinical Research

    Austin, Texas · Recruiting

  • Private Practice - Dr. Laila A. Hassan

    Houston, Texas · Recruiting

  • Radiance Clinical Research

    Lampasas, Texas · Recruiting

  • Quality Research Inc

    San Antonio, Texas · Recruiting

  • Tekton Research Inc

    San Antonio, Texas · Recruiting

  • Consano Clin Res-Shavano Park

    Shavano Park, Texas · Recruiting

  • Chrysalis Clinical Research

    St. George, Utah · Recruiting

  • The Vancouver Clinic

    Vancouver, Washington · Not yet recruiting

  • Castle Hill Medical Centre

    Castle Hill, New South Wales, Australia · Recruiting

  • Novatrials

    Charlestown, New South Wales, Australia · Recruiting

  • Hunter Medical Research Institute - Endocrinology and Diabetes

    New Lambton Heights, New South Wales, Australia · Not yet recruiting

  • Roger Chih Yu Chen

    Sydney, New South Wales, Australia · Recruiting

  • Royal Adelaide Hospital - Cardiology Department

    Adelaide, South Australia, Australia · Recruiting

  • Baker Heart and Diabetes Institute

    Melbourne, Victoria, Australia · Recruiting

  • Herz- und Diabeteszentrum NRW - Bad Oeynhausen

    Bad Oeynhausen, Germany · Recruiting

  • Medizinisches Versorgungszentrum Am Bahnhof Spandau GbR

    Berlin, Germany · Recruiting

  • DSP Bochum, Diabetes- und Stoffwechselpraxis

    Bochum, Germany · Not yet recruiting

  • Studiengesellschaft Dres. Könemann/Steinmann GbR

    Bünde, Germany · Not yet recruiting

  • InnoDiab Forschung GmbH

    Essen, Germany · Recruiting

  • Mesut Durmaz, Hof

    Hof, Germany · Recruiting

  • CRS Clinical Research Services Mannheim GmbH (hVIVO Mannheim)

    Mannheim, Germany · Recruiting

  • Versdias - Diabetologikum Amberg

    Amberg, Bavaria, Germany · Recruiting

  • Szent Margit Rendelőintézet Nonprofit Kft.

    Budapest, Hungary · Recruiting

Showing 40 of 70 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.